Century Therapeutics price target raised to $5 from $2 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor raised the firm’s price target on Century Therapeutics (IPSC) to $5 from $2 and keeps a Buy rating on the shares. Vertex has shown stem-cell islets can work and Sana has shown hypoimmune-edited islets can survive, the analyst tells investors in a research note. The firm says Century is trying to combine those two proof points in CNTY-813. It added CNTY-813 into its model with a 20% probability of approval and peak sales of $3.4B worldwide.